ABSTRACT: Allosteric ligands within a given chemotype can have the propensity to display a wide range of pharmacology, as well as unexpected changes in GPCR subtype selectivity, typically mediated by single-atom modifications to the ligand. Due to the unexpected nature of these "molecular switches", chemotypes with this property are typically abandoned in lead optimization. Recently, we have found that in vivo oxidative metabolism by CYP 450 s can also engender molecular switches within allosteric ligands, changing the mode of pharmacology and leading to unwanted toxicity. We required a higherthroughput approach to assess in vivo metabolic molecular switches, and we turned to a "synthetic liver", a 96 well kit of biomimetic catalysts (e.g., metalloporphyrins) to rapidly survey a broad panel of synthetic CYP 450 s' ability to oxidize/ "metabolize" an mGlu 5 PAM (VU0403602) known to undergo an in vivo CYP 450 -mediated molecular switch. While the synthetic CYP 450 s did generate a number of oxidative "metabolites" at known "hot spots", several of which proved to be pure mGlu 5 PAMs comparable in potency to the parent, the known CYP 450 -mediated in vivo ago-PAM metabolite, namely, VU0453103, was not formed. Thus, this technology platform has potential to identify hot spots for oxidative metabolism and produce active metabolites of small-molecule ligands in a high-throughput, scalable manner.
■ INTRODUCTION
From steep structure−activity relationships to family subtype selectivity issues to a potential lack of conservation of allosteric sites (e.g., functional activity) across species, allosteric GPCR drug discovery is fraught with challenges and development caveats. 1−4 However, no challenge is more daunting than that of "molecular switches", subtle structural changes to an allosteric ligand, often single-atom (e.g, introduction of a methyl, fluoro, amino, or hydroxyl moiety), that can reverse the mode of pharmacology (e.g., from a positive to a negative allosteric modulator, PAM to NAM, or vice versa) or change family subtype selectivity. 1−11 Fortunately, molecular switches are not present across all allosteric ligands but occur rather randomly within certain highly planar chemotypes, suggesting shallow induced fit pockets. While molecular switches have oftentimes been proven beneficial to gain entry to activity at a given receptor subtype (e.g., conversion of an mGlu 4 PAM to a selective mGlu 1 PAM 12 or an mGlu 5 PAM to a selective mGlu 3 NAM 13 ), they can also convert a nontoxic "pure" mGlu 5 PAM (VU0403602, 1) to neurotoxic mGlu 5 ago-PAM (VU0453103, 2) in vivo via an unexpected CYP 450 -mediated oxidation ( Figure 1 ). 14 The latter is challenging to de-risk, without multiple in vivo studies, performed with and without CYP 450 inhibitors, to ascertain parent and metabolite drug levels as well as neurotoxicity in rodent seizure models, and ultimately preparative CYP 450 incubations to identify the structure of the neurotoxic metabolite.
14 Within a fast-moving lead optimization effort, employing an in vivo de-risking strategy is not practical in terms of time, cost, and the likelihood of success. Based on these realities, we were intrigued by newly available biomimetic oxidation (BMO) kits, advertised as a "synthetic liver", mimicking the oxidative metabolism of multiple CYP 450 enzymes (e.g., synthetic metalloporphyrins). 15 Importantly, 96 individual synthetic livers are in each well of a 96 well plate, allowing an expansive survey of synthetic biotransformation of a ligand, coupled with production kits to readily scale the chemistry from any distinct well (e.g., synthetic CYP 450 ), enabling isolation and characterization of the "metabolite(s)". 12 If successful and productive, this could revolutionize our current, laborious approach to identifying allosteric ligand chemotypes susceptible to in vivo molecular switches and more readily focus optimization efforts on chemical series devoid of molecular switches.
■ RESULTS AND DISCUSSION
Knowing the in vitro and in vivo metabolism of 1, 11 as well as the relevant CYP 450 -mediated oxidative metabolites, we elected to assess the ability of a commercial BMO kit 15 to metabolize mGlu 5 PAM 1 and determine if any of the 96 synthetic livers could generate 2 or other known metabolites. Incubation of 1 with the screening BMO kit led to the production of only four metabolite-like compounds M3−M6 (Figure 2) . 16 The metabolite of greatest interest, the mGlu 5 + ion at m/z 241 and, second, fragmentation of the carbon nitrogen bond producing the benzoyl ion at m/z 223. For 1, the fragments associated with the water-assisted hydrolysis of the amide bond and the loss of the cyclobutyl group are also observed in the MS/MS and MS/MS/MS (MS 3 ) at m/z 242 and m/z 241, respectively. The last major fragment observed in both 1 and 2 is the decarboxylation producing a fragment with a m/z of 196. Since a standard of 2 was available, we were able to determine via retention time analysis that no detectable amount of 2, representing hydroxylation of the 3-position on the cyclobutyl moiety of 1, was produced by any of the 96 individual synthetic metalloporphyrins in the BMO kit. 16 The BMO screening kit did produce four other oxidative species, and analysis of the unknowns produced from 1 (M3− M6) were first analyzed by UPLC MS/MS/MS (UPLCMS 3   ) . 16 The parent ion of M3 was observed as the 1 These fragments at m/z 257 and 240 indicate that the oxygen was not attached to the cyclobutyl moiety like in 2, and thus, the fragment at m/z 214 indicates that there was a high likelihood that M3 is the N-oxide of 1, a metabolite detected in small amounts from traditional metabolite identification (MetID) studies. A simple comparison of the retention time, fragmentation patterns, and coinjection (average of the coinjection retention time analysis t R = 0.923 ± 0.000 min) with an available standard, synthesized to support the previous MetID studies, confirmed the identity of M3 as 4 (VU0409496), the N-oxide of 1 (Figure 3 ). 16 The biomimetic kit afforded 3.3 mg of M4. UPLCMS 3 of M4 found a parent ion of [M + H] + at m/z 241, which corresponded to the primary amide of 1. MS/MS of the parent ion gave two fragments, the water-assisted hydrolysis at m/z 242 and the major fragment at m/z 224, the benzoyl ion. The MS 3 of m/z 224 gave the decarboxylation fragment at m/z 196. All listed fragments indicate the identity of M4 as the primary amide of 1. The 1 H NMR of M4 displayed the same seven aromatic proton signals observed in 1 and lacked signals corresponding to the cyclobutyl moiety. 16 The only extra signal observed is the result of an increased barrier of rotation due to the intramolecular hydrogen bond observed in picolinamides resulting in the primary amide having two unique signals at δ H 7.80 (1H, br s, NH) and δ H 5.69 (1H, br s, NH). 17 The biomimetic kit also afforded 1.8 mg of M5. UPLCMS 3 
of M5 found a parent ion of [M + H]
+ at m/z 327, which corresponds to the addition of two oxygens to 1 (+32 Da; +O × 2). The first fragment resulted from the loss of water with m/z 309. The familiar loss of the cyclobutyl moiety and the water-assisted hydrolysis fragments were present at m/z 273 and 274; however, both fragments were still +32 Da heavier than 1 (m/z 241 and 242) when these same losses occurred. MS 3 of the major fragment m/z 273 indicated the loss of ammonia (−17 DA; −NH 3 ) to afford the benzoyl ion at m/z 256 followed by the loss of hydrogen cyanide (−27 Da; −HCN) at m/z 246 and decarboxylation at m/z 228, all of which are still +32 Da heavier than their counterpart's fragments from 1. These observations indicated that the two oxygens must be attached to the phenylethynylpyridine moiety and not as the N-oxide since HCN was lost and both oxygens still remained. H NMR revealed that no carbon−hydrogen bonds were replaced with carbon−oxygen bonds, indicating the ethynyl moiety as the most likely position for the addition of the two oxygens. In order to determine if oxidation occurred at the triple bond, an HMBC spectrum of M5 was obtained. Careful examination of the HMBC correlations from two of the picolinamide protons at δ H 9.11 and δ H 8.42 shows that they both display correlations to a ketone at δ C 191.1, while two protons from the 2-fluorobenzyl moiety at δ H 7.78 and δ H 7.74 both display correlations to a ketone at δ C 191.0. These observations support the transformation of the triple bond into a di-ketone assigning the potential structure as M5. Since the cyclobutyl moiety, picolinamide, and the 2-fluorobenzyl moiety were not modified, it left the ethynyl linkage as the only possible place for modification. If the ethynyl linkage was replaced with a ketone, then the loss of a carbon and the addition of an oxygen would be accounted for. It has also been shown to be possible to convert internal alkynes into shorter ketones with the use of porphyrins. 18 This assumption would assign the structure as M6. 16 In order to unambiguously confirm the structures and identities of M4−M6, we synthesized de novo these putative synthetic metabolites and compared spectral data and retention times (Scheme 1). Starting from commercial acid 5, a HATU-mediated amide coupling with cyclobutyl amine 6 afforded amide 7 in 85% yield. 19 A Sonogashira coupling between 7 and 3-fluorophenyl acetylene 8 provided 1 in 56% yield. Alternatively, 1 was also prepared via a different route. Direct Sonogashira coupling of acid 5 with 8 delivered acid 3, which could then be employed to access 1 via a standard amide coupling. Acid 3 can also be employed to give the primary carboxamide M4 (9) via an amide coupling sequence with (NH 4 ) 2 CO 3 , albeit in only 32% yield. 20 Following a known literature protocol, 21 the acetylene moiety in 1 was smoothly converted to the diketone M5 (10) by treatment with KMnO 4 . The last putative metabolite M6 (14) was accessed in two steps. A palladium-catalyzed acylation between boronic acid 11 and acid chloride 12 gave ketone 13 in low yield. Hydrolysis of the acid and another HATU-mediated amide coupling with 6 delivered M6 (14) in low yield over two steps (16%).
To confirm the structure of M4 as the primary amide of 1, it was synthesized (Scheme 1) and compared via retention time, fragmentation patterns, coinjection, and 1 H NMR comparison (see the Supporting Information). 16 The comparison analysis confirmed M4 as 9 (average of the coinjection retention time analysis t R = 1.047 ± 0.001 min), the primary amide of 1 ( Figure 4) . 16 Similarly, the proposed structure of M5, diketone 10, was synthesized on scale (Scheme 1) to aid in the confirmation of the structure. The analysis of the retention time (average of the coinjection retention time analysis t R = 0.957 ± 0.001 min), fragmentation patterns, coinjection, and 1 H NMR comparison confirmed the identity of M5 as the diketone 10.
16 Once again, to confirm the proposed structure of M6, 14 was synthesized on scale (Scheme 1). Analysis of the retention time (average of the coinjection retention time analysis t R = 0.969 ± 0.001 min), mass fragmentation patterns, coinjection, and 1 H NMR confirmed 14 as the structure for M4. 16 With M3−M6 in hand, they were evaluated in our standard mGlu 5 calcium mobilization functional assay, and M5 and M6 were inactive in both PAM and NAM modes; however, M3 and M4 proved more interesting.
The N-oxide, M3 (4, VU0409496) proved to be a potent, pure PAM in our standard screening assays (human EC 50 = 38.7 nM, pEC 50 = 7.41 ± 0.06, 71.5 ± 2.6% Glu Max; rat EC 50 = 28 nM, pEC 50 = 7.55 ± 0.06, 58.5 ± 3.6% Glu Max), roughly equipotent to the parent 1 and similarly devoid of mGlu 5 agonism (human EC 50 > 30 μM). This active metabolite was produced in very small quantities in native systems, but the BMO kit produced M3 in a significant amount to warrant characterization. Further evaluation of M3 found it to be non-CNS penetrant, with modest fraction unbound (f u (h, r) = 0.012, 0.033) and a metabolic activator of 3A4; therefore, M3 was not viable as a lead. The primary carboxamide M4 (VU6025968), a new synthetic oxidative metabolite not observed in native systems, was also an active mGlu 5 PAM. As we have sufficient quantity from the BMO production kit, we screened both the kit-produced M4 and synthetic M4 in the human mGlu 5 assay. The kit-produced M4 afforded a pure PAM profile, with an EC 50 of 510 nM (75% Glu Max), and the synthetic-derived M4 was equivalent (EC 50 = 315 nM, 77%, and no agonism noted up to 30 μM). Importantly, it was significant to identify active oxidative metabolites from the BMO kit that retained the desired mode of pharmacology (pure PAM versus ago-PAM) that were either produced in minor quantities or not observed in classical native system preparations.
■ CONCLUSIONS
In summary, the BMO kit proved to afford a highly expedient synthetic liver producing a number of known metabolites of 1, as well as novel synthetic metabolites in quantities sufficient for full characterization and biological assessment. MetID studies of the synthetic analogs were confirmed by independent synthesis, and unexpectedly based on the structures of M3− M6, two were potent pure mGlu 5 PAMs, that is, active metabolites. We hoped that the BMO kit would produce the potent, neurotoxic mGlu 5 ago-PAM (VU0453103, 2) of pure PAM 1, the result of an oxidative-metabolism-induced molecular switch; however, this was not observed in any of the 96 individual synthetic livers. Still, the technology platform has utility in producing on scale synthetic oxidative metabolites, but the biomimetic catalysts (e.g., metalloporphyrins) may not fully encompass all of the oxidative chemistry of endogenous CYP 450 s. Further work in this arena is in progress, and additional studies with other allosteric ligands will be reported in due course.
■ EXPERIMENTAL SECTION
General Methods. All reactions were carried out employing standard chemical techniques under air unless noted. Solvents used for extraction, washing, and chromatography were HPLC-grade. All reagents were purchased from commercial sources and were used without further purification. All microwave reactions were carried out in sealed tubes in a Biotage Initiator microwave synthesis reactor. Analytical HPLC was performed on an Agilent 1200 LCMS with a gradient of 5−95% MeCN in 0.1% TFA water over 1.5 min and UV detection at 215 and 254 nm along with ELSD detection and electrospray ionization, with all final compounds showing >95% purity. High-resolution mass spectra were obtained on an Agilent 6540 UHD Q-TOF with the ESI source. Automated flash column chromatography was performed on a Teledyne ISCO Combi-Flash system. Reversed-phase HPLC was performed on a Gilson preparative reversed-phase HPLC system comprising a 333 aqueous pump with solvent-selection valve, 334 organic pump, GX-271 or GX-281 liquid handler, two column switching valves, and a 155 UV detector. The UV wavelength for fraction collection was user-defined, with absorbance at 254 nm always monitored. The column used was Phenomenex Axia-packed Gemini C 18 (30 × 50 mm, 5 μm). For the acidic method, the mobile phase was CH 3 CN in H 2 O (0.1% TFA). Gradient conditions were 0.75 min equilibration followed by a user-defined gradient (starting organic percentage, ending organic percentage, duration), held at 95% CH 3 CN in H 2 O (0.1% TFA) for 1 min, 50 mL/min, 23°C. For the basic method, the mobile phase was CH 3 CN in H 2 O (0.05% v/v NH 4 OH). Gradient conditions were 0.75 min equilibration followed by a userdefined gradient (starting organic percentage, ending organic percentage, duration), held at 95% CH 3 CN. LCMS 3 experiments were carried out on an Agilent 1290 UPLC system coupled to a Thermo Scientific LTQ XL Linear Ion trap mass spectrometer using CH 3 CN and 10 mM ammonium formate with pH adjusted to 4.1 as the mobile phases with a Phenomenex Kinetex C 18 (2.6 μ, 2.1 × 50 mm, 100 Å column) held at 50°C with a CERA Temperature Controller at 1 mL/min. All NMR spectra were recorded on a 400 MHz Bruker AV-400 instrument. Compound Information. 5-Bromo-N-cyclobutylpicolinamide (7) . To a vial were added 5-bromopicolinic acid (5) (1.24 mmol), HATU (1.49 mmol), DMF (5 mL), DIPEA (4.95 mmol), and cyclobutylamine (6) (1.49 mmol). The mixture was allowed to stir for 30 min at rt after which time LCMS indicated product formation. The sample was filtered and purified on normal-phase chromatography using 0−20% EtOAc in hexanes to give 5-bromo-N-cyclobutylpicolinamide (7) as a white solid (85% yield). N-Cyclobutyl-5-((3-fluorophenyl)ethynyl)picolinamide (1). Route 1: To a microwave vial were added 5-bromo-Ncyclobutylpicolinamide (7) (0.98 mmol), trans-dichlorobis-(tripheylphosphine)palladium (II) (0.20 mmol), copper (I) iodide (0.20 mmol), DMF (4 mL), and DIPEA (9.80 mmol). The vial was capped and purged with N 2 , and then 3-fluorophenylacetylene (8) (4.90 mmol) was added. The vial was heated to 60°C in a microwave for 2 h after which time LCMS indicated product formation. The sample was filtered, concentrated, and resuspended in DMSO. The sample was purified on reversed-phase chromatography using 60−95% ACN in H 2 O/0.05% NH 4 OH to give N-cyclobutyl-5-((3-fluorophenyl)ethynyl)picolinamide (1) as an off-white solid (80% yield).
Route 2: 5-((3-Fluorophenyl)ethynyl)picolinic acid (3) (0.331 mmol) was dissolved in DMF (0.580 mL). DIPEA (0.660 mmol) was added, and the reaction solution was stirred for 30 min. HATU (0.400 mmol) was added, and the reaction solution was stirred for 30 min. Cyclobutylamine (6) (0.400 mmol) was added, and the reaction solution was stirred for 1 h at rt. At completion, the reaction solution was filtered and purified by reversed-phase chromatography to give N-cyclobutyl-5-((3-fluorophenyl)ethynyl)picolinamide (1) 5 -( ( 3 -F l u o r o p h e n y l ) e t h y n y l ) -N -( ( 1 R , 3 R ) -3 -hydroxycyclobutyl)picolinamide (2) . The compound was available as a 10 mM DMSO stock solution from previous work conducted by VCNDD. Synthesis and chiral resolution were previously reported. were dissolved in THF (1.8 mL). DIPEA (0.230 mmol) was added, and the reaction solution was stirred for 10 min at rt. Ammonium carbonate (0.620 mmol) was added, and the reaction solution was stirred overnight at rt. Solvent was concentrated via vacuum, a 1:1 saturated aqueous sodium bicarbonate/water solution (1.5 mL) was added, and the reaction solution was stirred for 2 h. The product was filtered, and the solvent was concentrated via vacuum. The resulting residue was purified by reversed-phase chromatography to give 5-((3-fluorophenyl)ethynyl)picolinamide (M4, 9) as a white solid (32% yield). 
